|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tan XL, Moyer AM, Fridley BL, Schaid DJ,
Niu N, Batzler AJ, Jenkins GD, Abo RP, Li L, Cunningham JM, et al:
Genetic variation predicting cisplatin cytotoxicity associated with
overall survival in lung cancer patients receiving platinum-based
chemotherapy. Clin Cancer Res. 17:5801–5811. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern
Cooperative Oncology, : Comparison of four chemotherapy regimens
for advanced non-small-cell lung cancer. N Engl J Med. 346:92–98.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hesse M and Arenz C: MicroRNA maturation
and human disease. Methods Mol Biol. 1095:11–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gommans WM and Berezikov E: Controlling
miRNA regulation in disease. Methods Mol Biol. 822:1–18. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Romero-Cordoba SL, Salido-Guadarrama I,
Rodriguez-Dorantes M and Hidalgo-Miranda A: miRNA biogenesis:
Biological impact in the development of cancer. Cancer Biol Ther.
15:1444–1455. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shin VY and Chu KM: MiRNA as potential
biomarkers and therapeutic targets for gastric cancer. World J
Gastroenterol. 20:10432–10439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saberi A, Danyaei A, Neisi N, Dastoorpoor
M and Tahmasbi Birgani MJ: MiR-328 may be considered as an oncogene
in human invasive breast carcinoma. Iran Red Crescent Med J.
18:e423602016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo X, Yang S, Zhou C, Pan F, Li Q and Ma
S: MicroRNA-328 enhances cellular motility through
posttranscriptional regulation of PTPRJ in human hepatocellular
carcinoma. Onco Targets Ther. 8:3159–3167. 2015.PubMed/NCBI
|
|
13
|
Arora S, Ranade AR, Tran NL, Nasser S,
Sridhar S, Korn RL, Ross JT, Dhruv H, Foss KM, Sibenaller Z, et al:
MicroRNA-328 is associated with (non-small) cell lung cancer
(NSCLC) brain metastasis and mediates NSCLC migration. Int J
Cancer. 129:2621–2631. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Steck PA, Pershouse MA, Jasser SA, Yung
WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T,
et al: Identification of a candidate tumour suppressor gene, MMAC1,
at chromosome 10q23.3 that is mutated in multiple advanced cancers.
Nat Genet. 15:356–362. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hopkins BD, Hodakoski C, Barrows D, Mense
SM and Parsons RE: PTEN function: The long and the short of it.
Trends Biochem Sci. 39:183–190. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S,
Malaponte G, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade
inhibitors: How mutations can result in therapy resistance and how
to overcome resistance. Oncotarget. 3:1068–1111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chalhoub N and Baker SJ: PTEN and the
PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
organization for research and treatment of cancer, National cancer
institute of the United States, National cancer institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 World Health Organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cao L, Chen J, Ou B, Liu C, Zou Y and Chen
Q: GAS5 knockdown reduces the chemo-sensitivity of non-small cell
lung cancer (NSCLC) cell to cisplatin (DDP) through regulating
miR-21/PTEN axis. Biomed Pharmacother. 93:570–579. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Galluzzi L, Vitale I, Michels J, Brenner
C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems
biology of cisplatin resistance: Past, present and future. Cell
Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng P, Chen L, Yuan X, Luo Q, Liu Y, Xie
G, Ma Y and Shen L: Exosomal transfer of tumor-associated
macrophage-derived miR-21 confers cisplatin resistance in gastric
cancer cells. J Exp Clin Cancer Res. 36:532017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gschwantler-Kaulich D, Tan YY, Fuchs EM,
Hudelist G, Köstler WJ, Reiner A, Leser C, Salama M, Attems J,
Deutschmann C, et al: PTEN expression as a predictor for the
response to trastuzumab-based therapy in Her-2 overexpressing
metastatic breast cancer. PLoS One. 12:e01729112017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soria JC, Lee HY, Lee JI, Wang L, Issa JP,
Kemp BL, Liu DD, Kurie JM, Mao L and Khuri FR: Lack of PTEN
expression in non-small cell lung cancer could be related to
promoter methylation. Clin Cancer Res. 8:1178–1184. 2002.PubMed/NCBI
|
|
27
|
Yu T, Liu L, Li J, Yan M, Lin H, Liu Y,
Chu D, Tu H, Gu A and Yao M: MiRNA-10a is upregulated in NSCLC and
may promote cancer by targeting PTEN. Oncotarget. 6:30239–30250.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lei L, Huang Y and Gong W: miR-205
promotes the growth, metastasis and chemoresistance of NSCLC cells
by targeting PTEN. Oncol Rep. 30:2897–2902. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K
and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN
and promotes growth and invasion in non-small cell lung cancer
(NSCLC). Clin Chim Acta. 411:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Du C, Zheng J, Lu X and Wang Y:
Downregulation of miR-18a or miR-328 inhibits the invasion and
migration of lung adenocarcinoma A549 cells. Xi Bao Yu Fen Zi Mian
Yi Xue Za Zhi. 32:1051–1054. 2016.(In Chinese). PubMed/NCBI
|
